Davis Polk advised the representatives of the initial purchasers in the offering.
Omnicell, Inc. completed the offering of $575 million aggregate principal amount of 0.25% convertible senior notes due 2025, including $75 million principal amount of convertible notes pursuant to the exercise in full of the initial purchasers’ option to purchase additional convertible notes. In addition, Davis Polk advised counterparties to convertible note hedge and warrant transactions in connection with the convertible notes offering. Omnicell’s common stock is listed on the Nasdaq Global Select Market under the symbol “OMCL.”
Omnicell, Inc. is a leading provider of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings.
J.P. Morgan Securities LLC and Wells Fargo Securities, LLC acted as representatives of the several initial purchasers.
The Davis Polk corporate team included partner Michael Kaplan (Picture) and associate Ariel Rivera. The Davis Polk equity derivatives team included partner Mark J. DiFiore, counsel Justin Michael, and associates Annie Li, Danielle Forni, Alex Yang and Ben Somogyi. Partner Michael Farber provided tax advice. Partner Frank J. Azzopardi provided intellectual property advice.
Involved fees earner: Frank Azzopardi – Davis Polk & Wardwell; Mark DiFiore – Davis Polk & Wardwell; Michael Farber – Davis Polk & Wardwell; Danielle Forni – Davis Polk & Wardwell; Michael Kaplan – Davis Polk & Wardwell; Annie Li – Davis Polk & Wardwell; Justin Michael – Davis Polk & Wardwell; Ariel Rivera – Davis Polk & Wardwell; Ben Somogyi – Davis Polk & Wardwell; Alex Yang – Davis Polk & Wardwell;
Law Firms: Davis Polk & Wardwell;